Coherus Biosciences | CHRS - Gastos De Venta Y Administración





Gastos De Venta Y Administración Cambio Fecha
AbbVie USD 3.58B 316M 2026-03
Acadia Pharmaceuticals USD 146.73M 21.82M 2025-12
Akebia Therapeutics USD 23.53M 3.19M 2025-12
ALKERMES USD 264.59M 77.4M 2026-03
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
Amarin USD 18.97M 1.03M 2025-12
Amgen USD 1.58B 354M 2026-03
Baxter International USD 728M 33M 2026-03
Biogen USD 554.3M 128.2M 2026-03
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Coherus Biosciences USD 15M 6.26M 2025-12
Eli Lilly USD 2.93B 198M 2026-03
Fujifilm JPY 215.83B 2.93B 2025-12
Gilead Sciences USD 1.78B 425M 2025-12
Ironwood Pharmaceuticals USD 33.33M 2.78M 2024-12
Merck USD 2.67B 180M 2026-03
Myriad Genetics USD 122.3M 6.7M 2025-12
Pacira USD 83.88M 7.99M 2026-03
Perrigo USD 255.9M 10.2M 2025-12
Pfizer USD 2.92B 1.16B 2026-03
PTC Therapeutics USD 87.2M 3.15M 2025-12
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Sarepta Therapeutics USD 105.38M 28.27M 2025-12
Teva Pharmaceutical Industries USD 1000M 120M 2026-03
Vertex Pharmaceuticals USD 493.7M 6.7M 2026-03
Xencor USD 17.04M 70.74M 2025-12
Zoetis USD 619M 40M 2025-12